This study revealed that exosomal mRNA can be isolated from human urine and analyzed without the use of a DRE or prostate massage. “This test, measuring the mRNA expression of PCA3, ERG, and SPDEF, can provide a high NPV to rule out the presence of high-grade clinically significant prostate cancer. Furthermore, out of 148 cases of GS7 or higher, only three patients with GS-predominant pattern 4 were missed, for a false-negative rate of less than 5%,” he reported.
Dr. McKiernan and his colleagues concluded that this novel, noninvasive urine exosome gene signature demonstrated excellent discrimination for the diagnosis of GS7 or higher prostate cancer for men presenting with indeterminate PSA results who would be candidates for first-time biopsy.
This study was performed in collaboration with and funded by Exosome Diagnostics, with coordination efforts through the Prostate Cancer Foundation.